Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. The company is headquartered in Jupiter, Florida.
| Revenue (TTM) | 40,450 |
| Gross Profit (TTM) | $-2.00M |
| EBITDA | — |
| Operating Margin | -10524.00% |
| Return on Equity | -6529.00% |
| Return on Assets | -130.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.08 |
| Price-to-Book | 227.66 |
| Price-to-Sales (TTM) | 257.29 |
| EV/Revenue | 320.5 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $48.22M |
| Float | $22.50M |
| % Insiders | 37.91% |
| % Institutions | 3.95% |
Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth
Investigational Oral Candidate JOTROL ™ Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available
NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering").
Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering.
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine
Jupiter, Florida--(Newsfile Corp. - May 4, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, announced today that it will be participating in the Market Movers Investor Summit on Tuesday May 5, 2026. The presentation will take place at 09:00 AM ET at the historic Bank of New York.
Jupiter, Florida--(Newsfile Corp. - April 13, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, will present at the Centri Capital Conference on Tuesday, April 14 at Nasdaq in New York City. Christer Rosén, Chairman and CEO will discuss the Company's recent performance and future growth plans.
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Jupiter Neurosciences, Inc. (NASDAQ: JUNS) resulting from allegations that Jupiter Neurosciences may have issued materially misleading business information to the investing public. So what: If you purchased Jupiter Neurosciences securities you may be entitled to compensation without payment of any out of pocket fees or costs th.
